Clobetasone butyrate
(Synonyms: 丁酸氯倍他松) 目录号 : GC39362
Clobetasone butyrate is a new corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions.
Cas No.:25122-57-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Clobetasone butyrate is a new corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions.
| Cas No. | 25122-57-0 | SDF | |
| 别名 | 丁酸氯倍他松 | ||
| Canonical SMILES | C[C@@]1(C2)[C@](C(CCl)=O)(OC(CCC)=O)[C@@H](C)C[C@@]1([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)[C@@]3(F)C2=O)=O | ||
| 分子式 | C26H32ClFO5 | 分子量 | 478.98 |
| 溶解度 | DMSO: ≥ 250 mg/mL (521.94 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0878 mL | 10.4388 mL | 20.8777 mL |
| 5 mM | 0.4176 mL | 2.0878 mL | 4.1755 mL |
| 10 mM | 0.2088 mL | 1.0439 mL | 2.0878 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Eumovate (Clobetasone butyrate 0.05%) cream: a review of clinical efficacy and safety
J Dermatolog Treat 2003 Jun;14(2):71-85.PMID:12775314DOI:10.1080/09546630310004180.
Topical steroid creams and ointments have been available as over-the-counter (OTC) medications for the self treatment of acute dermatitis and other steroid responsive skin disorders for more than ten years. Despite earlier fears, widespread availability and use of these creams is not associated with clinically significant adverse effects. In dermatological practice, hydrocortisone 1% remains the mainstay of treatment for facial eczema, but it is often not effective in eczema affecting other body areas. Eumovate(TM) (Clobetasone butyrate 0.05%) cream has recently been made available as a pharmacy medication for the short-term management of acute eczema and allergic dermatitis by adults and children aged 10 or older, based on evidence derived from clinical trials involving over 3500 patients. This review summarises the key efficacy and safety data derived from 29 clinical trials and the post-licensing pharmacovigilance safety information, which supported the reclassification of this product for OTC use. These data show Clobetasone butyrate 0.05% is more effective than 1.0% hydrocortisone in the treatment of eczema and more effective than flurandrenolone 0.0125% (p=0.01%) and a potent topical steroid hydrocortisone butyrate (p<0.05), in the treatment of psoriasis. A review of the effect of topical steroids on skin thickness concluded that, following short term application, there was no clinically significant difference between hydrocortisone 1.0% and Clobetasone butyrate 0.05% in terms of potential for skin thinning. Similarly, even under extreme conditions, Clobetasone butyrate 0.05% has negligible systemic absorption and has almost no effect on HPA axis function.
Seborrhoeic dermatitis of the scalp
BMJ Clin Evid 2015 May 27;2015:1713.PMID:26016669doi
Introduction: Seborrhoeic dermatitis affects a variable proportion of the general population, ranging from 3% to 10%. Malassezia yeast species (previously referred to as Pityrosporum) are thought to be the responsible organisms, and cause inflammation by still poorly defined mechanisms. Seborrhoeic dermatitis tends to relapse after treatment. Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of topical treatments for seborrhoeic dermatitis of the scalp in adults? We searched: Medline, Embase, The Cochrane Library, and other important databases up to November 2013 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). Results: We found 14 studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: bifonazole, ciclopirox, ketoconazole, pyrithione zinc, selenium sulfide, tar shampoo, terbinafine, and topical corticosteroids (betamethasone valerate, clobetasol propionate, Clobetasone butyrate, hydrocortisone, mometasone furoate).
Clobetasone butyrate and hydrocortisone butyrate in the treatment of eczema: a double-blind comparison
Curr Med Res Opin 1979;6(3):165-7.PMID:391489DOI:10.1185/03007997909109415.
Forty patients with symmetrical eczematous lesions on their extremities were treated in a double-blind fashion with 0.05% Clobetasone butyrate and 0.1% hydrocortisone butyrate in cream bases. After 2 weeks of treatment, a preference for Clobetasone butyrate was observed in 7 cases, for hydrocortisone butyrate in 9 cases and in 24 cases both sides responded equally. The lesions on both sides improved steadily throughout the study in all cases. When completing the trial after 2-weeks' treatment, the clobetasone butyrate-treated lesions had healed in 8 cases and the hydrocortisone butyrate-treated lesions in 10 cases. No local side-effects were observed.
Topical treatment of eczematous external otitis involving the ear canal: long-term results of a trial comparing pimecrolimus 1 per cent versus Clobetasone butyrate 0.05 per cent
J Laryngol Otol 2022 Jul;136(7):635-638.PMID:34991759DOI:10.1017/S002221512100445X.
Background: Eczematous external otitis is a common chronic condition that can have a significant impact on the life of sufferers, causing constant discomfort and pruritus, and leading to sleep deprivation. Treatment is based on the use of topical steroids, moisturisers and occasionally antibiotics. Results, however, can be disappointing, especially over the long term. Methods: This study compared the long-term response to pimecrolimus, administered to a group of 11 patients, against Clobetasone butyrate, administered to an equivalent number of patients. Response to the treatment was assessed and statistically analysed at 3 and 12 months. Conclusion: Whereas the degree of improvement following the use of pimecrolimus and Clobetasone butyrate was similar for the two groups at month 3, a highly statistically significant difference was documented at month 12, with a much greater and sustained improvement in the pimecrolimus group.
Clobetasone butyrate eye drops. Effect on ocular inflammation and intraocular pressure
Trans Ophthalmol Soc U K (1962) 1981;101(1):27-9.PMID:6764318doi
Clobetasone butyrate eye drops comprise a new steroid preparation which has been investigated in two comparable, double-blind, multicentre clinical trials in patients with ocular inflammation. One study compared Clobetasone butyrate with betamethasone phosphate eye drops (205 patients) and the other study compared corresponding preparations containing neomycin (169 patients). There was no difference between the responses to Clobetasone butyrate and betamethasone. An excellent or good response was obtained in 73 per cent of patients treated with Clobetasone butyrate, 75 per cent with betamethasone, 69 per cent with Clobetasone butyrate formulated with neomycin, and 76 per cent with betamethasone formulated with neomycin. Patients who were known to react with a rise of intraocular pressure (IOP) to steroids were treated with Clobetasone butyrate eye drops in one eye and either prednisolone eye drops (6 patients) or hydrocortisone eye drops (4 patients) in the other eye. The doses were continued for 6 weeks, or less if the IOP rose more than 10 mm Hg in one eye. All patients experienced a greater intraocular pressure rise in the eye treated with prednisolone or hydrocortisone. The mean changes in IOP were 9 mm Hg for prednisolone compared to 2 mm Hg for Clobetasone butyrate (P less than 0.05 Wilcoxon signed ranks test) and 16 mm Hg for hydrocortisone compared to 2 mm Hg for Clobetasone butyrate.